A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma

NCT00116103 Phase 2 COMPLETED

The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.

Details

Lead sponsor	Astellas Pharma Inc
Phase	Phase 2
Status	COMPLETED
Start date	2005-06
Completion	2006-04

Conditions

• Asthma

Interventions

• Tacrolimus Inhalation Aerosol

Primary outcomes

• The primary outcome is the change in FEV1 from baseline to end-treatment.

Countries

United States